There appeared to be a treatment effect for OS favoring nab-paclitaxel plus gemcitabine over gemcitabine alone in poor-prognosis subgroups defined by these factors ( HR = @ , P < @ for CA@-@ level median and HR = @ , P = @ for NLR > @ ) .